Title |
c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target
|
---|---|
Published in |
BMC Cancer, June 2015
|
DOI | 10.1186/s12885-015-1450-3 |
Pubmed ID | |
Authors |
Yohei Ozawa, Yasuhiro Nakamura, Fumiyoshi Fujishima, Saulo JA Felizola, Kenichiro Takeda, Hiroshi Okamoto, Ken Ito, Hirotaka Ishida, Takuro Konno, Takashi Kamei, Go Miyata, Noriaki Ohuchi, Hironobu Sasano |
Abstract |
c-Met is widely known as a poor prognostic factor in various human malignancies. Previous studies have suggested the involvement of c-Met and/or its ligand, hepatocyte growth factor (HGF), in esophageal squamous cell carcinoma (ESCC), but the correlation between c-Met status and clinical outcome remains unclear. Furthermore, the identification of a novel molecular therapeutic target might potentially help improve the clinical outcome of ESCC patients. The expression of c-Met and HGF was immunohistochemically assessed in 104 surgically obtained tissue specimens. The correlation between c-Met/HGF expression and patients' clinicopathological features, including survival, was evaluated. We also investigated changes in cell functions and protein expression of c-Met and its downstream signaling pathway components under treatments with HGF and/or c-Met inhibitor in ESCC cell lines. Elevated expression of c-Met was significantly correlated with tumor depth and pathological stage. Patients with high c-Met expression had significantly worse survival. In addition, multivariate analysis identified the high expression of c-Met as an independent prognostic factor. Treatment with c-Met inhibitor under HGF stimulation significantly inhibited the invasive capacity of an ESCC cell line with elevated c-Met mRNA expression. Moreover, c-Met and its downstream signaling inactivation was also detected after treatment with c-Met inhibitor. The results of our study identified c-Met expression as an independent prognostic factor in ESCC patients and demonstrated that c-Met could be a potential molecular therapeutic target for the treatment of ESCC with elevated c-Met expression. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 15% |
United Kingdom | 1 | 4% |
Japan | 1 | 4% |
Brazil | 1 | 4% |
Netherlands | 1 | 4% |
Unknown | 18 | 69% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 20 | 77% |
Science communicators (journalists, bloggers, editors) | 5 | 19% |
Scientists | 1 | 4% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Austria | 1 | 4% |
Unknown | 23 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 5 | 21% |
Researcher | 4 | 17% |
Student > Master | 3 | 13% |
Student > Ph. D. Student | 3 | 13% |
Professor | 2 | 8% |
Other | 3 | 13% |
Unknown | 4 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 38% |
Biochemistry, Genetics and Molecular Biology | 3 | 13% |
Agricultural and Biological Sciences | 3 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Psychology | 1 | 4% |
Other | 1 | 4% |
Unknown | 6 | 25% |